The MAI-FOIE cohort will be a French multicenter cohort with the development of a biobank including patients with autoimmune, metabolic and medicated liver diseases

The MAI-FOIE cohort will be a prospective cohort of patients with autoimmune liver diseases followed up in 13 French centers. The multicentric nature of the cohort is a major asset, enabling the enrolment of a broad spectrum of patients, from those naïve to any immunomodulatory treatment to those refractory to therapies. The goal is to identify different treatment response profiles, markers of remission and markers of relapse risk after discontinuation of immunosuppressants in order to improve patient care.

AIH (Auto-Immune Hepatitis) patients :

Inclusion Criteria :

1. age≥10 years old

2. weight≥25kg

3. AIH (with or without the presence of an overlap) whose diagnosis is validated by at least 2 of the following criteria :

   • ALT>2N or IgG>1.1N
   • Presence of autoantibodies : ANA (antinuclear), ML (anti-smooth muscle), SLA (anti-soluble liver antigen), LKM1 (anti-endoplasmic reticulum), LC1 (anti-liver cytosol)
   • Presence of interface hepatitis on biopsy

4. signing of a written consent form for participation in the study and for the storage of biological samples research

Control patients :

1. age≥18 years old

2. weight≥37kg

3. Patient with one of the following 3 conditions :

   • Primary Biliary Cholangitis
   • Metabolic steatohepatitis
   • Drug induced hepatitis

Exclusion Criteria :

Positive HIV serology HBV infection Positive HCV serology and PCR Patients under guardianship or curatorship

Patients from 10 years old to patients without limit age, male or female, with Auto-Immune Hepatitis or Metabolic steatohepatitis or Drug induced Hepatitis